Register

Pancreatic Cancer   

Questions discussed in this category

Would you offer consolidative full dose chemo-RT for local residual pancreatic disease in a patient with stage IV pancreatic adenocarcinoma with excellent response after induction chemotherapy?
Would you ever consider this approach for an initially polymetastatic patient?
2 Answers available
How long should surgery be delayed in a patient with localized, resectable pancreatic cancer who developed acute pancreatitis following EUS guided biopsy?
And if delayed, should chemotherapy be started?
2 Answers available
Should immunotherapy be added to standard of care neoadjuvant chemotherapy in borderline resectable MSI-H adenocarcinoma of pancreas?
Is there data to support this approach?
2 Answers available
How would you approach a locally advanced ampullary carcinoma with BRCA1 mutation whose Whipple showed complete pathologic response after 5 cycles of neoadjuvant mFOLFIRINOX?
Patient refuses further mFOLFIRINOX but may be open to less aggressive regimens. Is there any role for PARP inhibitors?
1 Answer available
For insurance, how do you justify medical necessity for IMRT to the pancreas in the preoperative, unresectable, and post-operative settings?
1 Answer available
Would you favor starting with pembrolizumab or chemotherapy for a metastatic MSI-high pancreatic ductal adenocarcinoma?
Would your recommendation change in a patient having pain from disease and you wanted a quick response?
1 Answer available
What are your top takeaways from ASCO GI 2023?
What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice? ...
8 Answers available
Would you recommend adjuvant chemotherapy for a patient with subcentimeter pancreatic adenocarcinoma incidentally found during a Whipple resection for high risk IPMN?
1 Answer available
In light of the recently published Alliance A021501 trial, what is your approach to incorporating SBRT for the treatment of borderline resectable pancreatic cancer?
A021501 trial: mFOLFIRINOX vs mFOLFIRINOX with hypofractionated radiation (Katz et al., PMID 35834226)
1 Answer available
How would you treat single celiac focus of adenocarcinoma of unknown primary?
Would you consider SBRT as post-chemo consolidation for a patient with a single unresectable focus of metastatic adenocarcinoma at the celiac axis?&nb...
1 Answer available
What is your preferred first line regimen for a patient with BRCA+ metastatic pancreatic cancer with poor performance status?
2 Answers available
What third line treatment do you consider for a patient with metastatic pancreatic cancer with good functional status and no targetable mutations after progression on FOLFIRINOX and gemcitabine/nab-paclitaxel?
3 Answers available


Papers discussed in this category

N. Engl. J. Med., 2019 Jun 02
Maintenance Olaparib for Germline -Mutated Metastatic Pancreatic Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-01-20
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Pancreatology, 2020 Oct 18
Nanoliposomal irinotecan (Nal-IRI)-based chemotherapy after irinotecan -based chemotherapy in patients with pancreas cancer.
Lancet (London, England), 2016-02-06
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
European journal of cancer (Oxford, England : 1990), 2019-02
NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
JAMA,
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.
J Clin Oncol, 2022 Jan 27
Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial.
BMC Cancer, 2021 Mar 23
Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial.
Int J Radiat Oncol Biol Phys, 2019 Jan 23
Patterns of Local Failure After Stereotactic Body Radiation Therapy and Sequential Chemotherapy as Initial Treatment for Pancreatic Cancer: Implications of Target Volume Design.
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2007-11
Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer.
Annals of surgery, 2010-03
Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas.
Cancer, 2016-02-15
The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
Cancer, 2019-01-01
Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer.
HPB : the official journal of the International Hepato Pancreato Biliary Association, 2017-07
Does adjuvant therapy improve overall survival for stage IA/B pancreatic adenocarcinoma?
N. Engl. J. Med.,
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
The New England journal of medicine, 2013-10-31
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
Lancet, 2021 Jun 05
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Eur J Cancer, 2018 Aug 24
A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.
NEJM Evidence, 2022 Jun 1
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
J Clin Oncol, 2019 Nov 04
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Gut, 2020 Apr 29
Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications.
JAMA Oncol, 2022 Apr 1
Palliative Radiation for Advanced Central Lung Tumors With Intentional Avoidance of the Esophagus (PROACTIVE): A Phase 3 Randomized Clinical Trial.
Int J Radiat Oncol Biol Phys, 2023 Mar 01
Alleviating morbidity from locally advanced breast cancer using a practical and short radiotherapy regime: Results of the HYPORT palliative studies.
Seminars in radiation oncology, 2002 Jul
Intensity-modulated radiation therapy: the inverse, the converse, and the perverse.
American journal of clinical oncology, 2023 Dec 22
Executive Summary of the American Radium Society Appropriate Use Criteria for Neoadjuvant Therapy for Nonmetastatic Pancreatic Adenocarcinoma: Systematic Review and Guidelines.
Int J Radiat Oncol Biol Phys, 2022 Jul 04
A Critical Review of the Role of Local Therapy for Oligometastatic Gastrointestinal Cancer.
Lancet (London, England), 2023 Dec 14
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.

Related Topics

Copyright © 2024 theMednet
All Rights Reserved.